Newish Technology (Beijing) Co.,Ltd. Report issue

Government Phase 1 Phase 2

Organization Overview

First Clinical Trial
2018
NCT03432156
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2023

Timeline

NOW
  • Now

Alternative names

Newish Technology (Beijing) Co., Ltd. | Newish Technology (Beijing) Co.,Ltd.

Active Ingredients

Drugs in Phase 2 Trials (2)

autologous lymphocytes (1 trial)

autologous T cell memory cells (2 trials)

Drugs in Phase 1 Trials (1)

NWRD06 (1 trial)

Drugs in Other Trials (1)

nwrd08 (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Carcinoma, Non-Small-Cell Lung (Phase 2)

Cholangiocarcinoma (Phase 2)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 5
  • # of Trial APIs: 4